OMNIAB INC (OABI) competitors & alternatives
Health Care · NASDAQ
OMNIAB INC (OABI)'s top competitors and alternatives — its most similar public companies — include Regeneron Pharmaceuticals (REGN), Bristol Myers Squibb (BMY), Exelixis (EXEL), CYTOMX THERAPEUTICS INC (CTMX), ADC THERAPEUTICS SA (ADCT), ZYMEWORKS INC (ZYME), NURIX THERAPEUTICS INC (NRIX), ABSCI CORP (ABSI), GENERATE BIOMEDICINES INC (GENB), SUTRO BIOPHARMA INC (STRO), VOYAGER THERAPEUTICS INC (VYGR) and XENCOR INC (XNCR). These are OMNIAB INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top OABI competitors & alternatives
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
-
ZYMEWORKS INCZYMEHealth Care
A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation…
$23.36 (as of 2026-07-22) · market cap $1.7B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
ABSCI CORPABSIHealth Care
Absci is a clinical-stage drug developer leveraging a generative AI platform to rapidly design and validate novel, differentiated antibody therapeutics for…
$8.24 (as of 2026-07-22) · market cap $1.4B
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
SUTRO BIOPHARMA INCSTROHealth Care
Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for…
$23.40 (as of 2026-07-22) · market cap $388M
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
-
XENCOR INCXNCRHealth Care
Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific…
$19.51 (as of 2026-07-22) · market cap $1.4B
Not quite? Describe exactly what you want →
Peers are OMNIAB INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: OMNIAB INC (OABI).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.